within Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA31_Pegcetacoplan;

model Pegcetacoplan
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 4.38888888888889e-09,
    adminDuration = 600,
    adminMass = 1080 / 1000000,
    adminCount = 1,
    Vd = 0.0039,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Pegcetacoplan</td></tr><tr><td>ATC code:</td><td>S01XA31</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1080</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.9</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.0158</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Pegcetacoplan is a complement C3 inhibitor, primarily used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It is a pegylated cyclic peptide approved for clinical use, offering targeted therapy by inhibiting the complement cascade at the level of C3, thereby controlling hemolysis related to PNH.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in adults with PNH following subcutaneous administration.</p><h4>References</h4><ol><li><p>Crass, RL, et al., &amp; Langdon, G (2024). Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Drugs in R&amp;D</i> 24(4) 563–573. DOI:<a href=\"https://doi.org/10.1007/s40268-024-00500-7\">10.1007/s40268-024-00500-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39612158/\">https://pubmed.ncbi.nlm.nih.gov/39612158</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01XA31 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Pegcetacoplan;
